The Zhitong Finance App learned that Gacos-B (01167) rose more than 9%. As of press release, it had risen 8.45% to HK$616, with a turnover of HK$11.205,800.
China Post Securities recently reported that the company currently has 5 pipelines (KRAS G12C, SHP2, BET, Aurora A, and CD73) in the clinical stage, and will release multiple dose climbing data in 2023. Various preclinical pipelines, including KrasMulti inhibitors, P53 Y220C activators, and immunostimulatory ADCs, will submit IND applications in 2023-2024. Furthermore, the bank believes KRAS G12C inhibitors are expected to be marketed in China in 2024. The first one has a “buy” rating, with a target price of HK$13.8.
Earlier, Gacos issued an announcement stating that the KRAS G12C inhibitor JAB-21822 was granted breakthrough therapeutic drug certification by the Drug Evaluation Center (CDE) of China's National Drug Administration. This certification is based on JAB-21822's early good efficacy and safety data. The certification of the breakthrough treatment will help speed up the review and registration of the drug market and speed up patients' early access to drugs.
